Endometrial Cancer Trial, Recruiting (NCT04857528)

Endometrial Cancer Trial, Recruiting NCT04857528 Sponsor: University of Chicago Condition: Endometrial Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT04857528 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Endometrial Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with stage I-III anal cancer or stage I-IVA cervical cancer that has tested positive for a protein called p16 (based on a lab test).
You are 18 years of age or older.
Your doctors are planning to use radiation therapy as your main treatment, with or without additional medications given at the same time.

Who may not be able to join:

You have anal cancer that is not linked to specific strains of the HPV virus (HPV types 16, 18, 31, 33, or 35) (confirm with trial site).
Your radiation therapy is planned to be given after surgery, rather than as the main treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Christina Son, MD, University of Chicago

Phone: 773-702-6870

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04857528

Sponsor: University of Chicago

Phase: Not Applicable

Status: Recruiting

Condition: Endometrial Cancer

Trial contact: 773-702-6870

More information: https://clinicaltrials.gov/study/NCT04857528

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with stage I-III anal cancer or stage I-IVA cervical cancer that has tested positive for a protein called p16 (based on a lab test).
You are 18 years of age or older.
Your doctors are planning to use radiation therapy as your main treatment, with or without additional medications given at the same time.

Who may not be able to join:

You have anal cancer that is not linked to specific strains of the HPV virus (HPV types 16, 18, 31, 33, or 35) (confirm with trial site).
Your radiation therapy is planned to be given after surgery, rather than as the main treatment.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Chicago

Registry

ClinicalTrials.gov

Start date

6 October 2020

Est. completion

15 November 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Rate of Participants With Detectable Circulating HPV DNA in Blood/Tumor Samples

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov